Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 15mg+7,5mg 30tk; 15mg+7,5mg 20tk; 15mg+7,5mg 14tk; 15mg+7,5mg 60tk; 15mg+7,5mg 28tk

Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 10mg+5mg 14tk; 10mg+5mg 56tk; 10mg+5mg 28tk; 10mg+5mg 30tk; 10mg+5mg 98tk; 10mg+5mg 60tk; 10mg+5mg 100tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 5mg+2,5mg 10tk; 5mg+2,5mg 7tk; 5mg+2,5mg 14tk; 5mg+2,5mg 98tk; 5mg+2,5mg 100tk; 5mg+2,5mg 28tk; 5mg+2,5mg 56tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 10mg+5mg 10tk; 10mg+5mg 50tk; 10mg+5mg 14tk; 10mg+5mg 30tk; 10mg+5mg 60tk

Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 80mg+40mg 28tk; 80mg+40mg 14tk; 80mg+40mg 60tk; 80mg+40mg 30tk; 80mg+40mg 56tk; 80mg+40mg 98tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 40mg+20mg 30tk; 40mg+20mg 7tk; 40mg+20mg 20tk; 40mg+20mg 14tk; 40mg+20mg 100tk; 40mg+20mg 28tk; 40mg+20mg 10tk

Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 60mg+30mg 28tk; 60mg+30mg 56tk; 60mg+30mg 14tk; 60mg+30mg 100tk; 60mg+30mg 60tk; 60mg+30mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastilised ained - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Euroopa Liit - eesti - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - totsilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosupressandid - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Euroopa Liit - eesti - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitasoonvesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - pioglitazone on näidustatud ravi tüüp-2 diabeet:kui monotherapy:patsientidel (eelkõige ülekaalulistel patsientidel) ebapiisavalt kontrollitud toitumise ja treeningu kohta, kellele metformiin ei sobi, sest vastunäidustusi või talumatust;as dual suukaudne ravi koos:metformiin, patsientidel (eriti ülekaalulistel patsientidel), millel piisavalt glycaemic kontrolli hoolimata maksimaalne talutav annus monotherapy koos metformiin;a sulphonylurea, ainult patsientidel, kes näitavad, sallimatuse, et metformiin või kellele metformiin on vastunäidustatud, ebapiisav glycaemic kontrolli hoolimata maksimaalne talutav annus monotherapy koos sulphonylurea;kui kolmekordse suukaudse ravi koos:metformiin ja sulphonylurea, patsientidel (eriti ülekaalulistel patsientidel), millel piisavalt glycaemic kontrolli hoolimata dual suukaudne ravi. pioglitazone on ka näidatud koos insuliini tüüp-2 diabeet patsiendid, kellel on ebapiisav glycaemic kontrolli insuliini, kellele metformiin ei sobi, sest vastunäidustusi või talumatust.